2. Apoptosis
  3. Apoptosis
  4. Visilizumab

Visilizumab  (Synonyms: Anti-Human CD3E Recombinant Antibody; HuM291)

Cat. No.: HY-P99332 Purity: 98.43%
COA

Molarity Calculator

Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research.

For research use only. We do not sell to patients.

Visilizumab Chemical Structure

Visilizumab Chemical Structure

CAS No. : 219716-33-3

Size Price Stock Quantity
1 mg USD 400 In-stock
5 mg USD 1200 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Visilizumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research[1].

In Vitro

Visilizumab induces dose- and time-dependent apoptosis of lamina propria T cells. Visilizumab-induces apoptosis of lamina propria T cells is dependent on caspase 3 and 8, but not caspase 9 activation and does not involve the Fas/FasL pathway[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Visilizumab Related Antibodies

Apoptosis Analysis[1]

Cell Line: Lamina propria T cells
Concentration: 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL
Incubation Time: 2 hours, 4 hours, 20 hours, 24 hours, 48 hours
Result: Induced dose- and time-dependent apoptosis of lamina propria T cells.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Volociximab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 98.43%

COA (231 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Visilizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Visilizumab219716-33-3Anti-Human CD3E Recombinant Antibody HuM291HuM291HuM 291HuM-291ApoptosisCD3low-Fc receptormonoclonal IgG2 antibodyulcerative colitisCrohn's diseaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Visilizumab
Cat. No.:
HY-P99332
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.